Endpoints
SECONDARY
The primary endpoints were to assess the maximum tolerated dose (MTD), safety and the recommended phase II dose (RP2D) of pyrotinib monotherapy and pyrotinib in combination with docetaxel. The secondary endpoints included PK evaluation and preliminary efficacy of pyrotinib monotherapy and pyrotinib combined with docetaxel.